This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CORI Corium International (CORI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Corium International Stock (NASDAQ:CORI) 30 days 90 days 365 days Advanced Chart Get Corium International alerts:Sign Up Key Stats Today's Range$12.68▼$12.6850-Day Range N/A52-Week Range$7.17▼$13.93VolumeN/AAverage Volume577,723 shsMarket Capitalization$459.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California. Read More Receive CORI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corium International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CORI Stock News HeadlinesGlobal Vaccine Delivery Devices Market Analysis & Forecast 2024-2034May 27, 2024 | finance.yahoo.comQUEBEC AI INNOVATION: COGINOV AND CORIUM JOIN FORCES FOR ACCELERATED GROWTHJanuary 22, 2024 | ca.finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 29 at 2:00 AM | Brownstone Research (Ad)Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across AsiaAugust 10, 2023 | businesswire.comBest International Student LoansJuly 6, 2023 | investopedia.comThe 5 Best International Travel Insurance Companies for 2023May 23, 2023 | travel.usnews.comGlobal 2023, Passive Transdermal Drug Delivery Market Analysis of New Report 2030May 15, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Share by 2031April 28, 2023 | marketwatch.comSee More Headlines CORI Stock Analysis - Frequently Asked Questions How were Corium International's earnings last quarter? Corium International, Inc. (NASDAQ:CORI) announced its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. The biopharmaceutical company earned $7.67 million during the quarter, compared to analysts' expectations of $6.72 million. Corium International had a negative trailing twelve-month return on equity of 276.89% and a negative net margin of 155.21%. What other stocks do shareholders of Corium International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corium International investors own include Bristol Myers Squibb (BMY), Intelsat (I), Energy Transfer (ET), Iovance Biotherapeutics (IOVA), Exelixis (EXEL), SunCoke Energy Partners (SXCP) and Cypress Semiconductor (CY). Company Calendar Last Earnings8/09/2018Today8/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CORI CIK1594337 Webwww.coriumgroup.com Phone650-298-8255FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.79 million Net Margins-155.21% Pretax MarginN/A Return on Equity-276.89% Return on Assets-57.52% Debt Debt-to-Equity Ratio2.83 Current Ratio7.61 Quick Ratio7.47 Sales & Book Value Annual Sales$31.86 million Price / Sales14.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book28.18Miscellaneous Outstanding Shares36,250,000Free FloatN/AMarket Cap$459.65 million OptionableOptionable Beta0.87 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CORI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corium International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corium International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.